Anna Halpern

Trials

Studies that name Anna Halpern as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:04 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07148947 · Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

  University of Washington · recruiting · Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm · principal investigator
• N/A
  NCT06710418 · Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

  University of Washington · recruiting · Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma · principal investigator
• Ph2
  NCT04282187 · Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

  University of Washington · recruiting · Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT03012672 · Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

  University of Washington · completed · Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm · principal investigator
• Ph1/Ph2
  NCT02728050 · Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  University of Washington · completed · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome · principal investigator
• N/A
  NCT02226497 · Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

  Fred Hutchinson Cancer Center · terminated · Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph1/Ph2
  NCT01729845 · Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

  Fred Hutchinson Cancer Center · completed · Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 20:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Center Administration
  P30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026
  Named on NCT03012672, NCT02728050, NCT02226497, NCT01729845